Search alternatives:
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
ms decrease » _ decrease (Expand Search), nn decrease (Expand Search), use decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
50 ms » 50 mg (Expand Search), 50 mm (Expand Search)
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
Characteristics of Gasless Combustion of Core–Shell Al@NiO Microparticles with Boosted Exothermic Performance
Published 2024“…The PM composite was not able to be ignited at all by a 5 W laser, while the core–shell counterpart ignited at 2.55 ms and was completely combusted within 6.50 ms accompanying a violent impulse.…”
-
92
Characteristics of Gasless Combustion of Core–Shell Al@NiO Microparticles with Boosted Exothermic Performance
Published 2024“…The PM composite was not able to be ignited at all by a 5 W laser, while the core–shell counterpart ignited at 2.55 ms and was completely combusted within 6.50 ms accompanying a violent impulse.…”
-
93
Description of the myofascial release techniques.
Published 2024“…</b></p><p>Results</p><p>Thirty-eight patients (14 in CRT, 14 in CRT+MRT, and 10 in RUHB), with a mean age of 55 years and 50% male, completed the study. …”
-
94
Study flow diagram.
Published 2024“…</b></p><p>Results</p><p>Thirty-eight patients (14 in CRT, 14 in CRT+MRT, and 10 in RUHB), with a mean age of 55 years and 50% male, completed the study. …”
-
95
Clinical characteristics of the study population.
Published 2024“…</b></p><p>Results</p><p>Thirty-eight patients (14 in CRT, 14 in CRT+MRT, and 10 in RUHB), with a mean age of 55 years and 50% male, completed the study. …”
-
96
-
97
-
98
-
99
Analysis of NIST Monoclonal Antibody Reference Material Glycosylation Using the LC–MS/MS-Based Glycoproteomic Approach
Published 2020“…Here, we applied an LC–MS/MS-based glycoproteomics approach to characterize Fc glycans of an NISTmAb reference material (RM) 8671 (sample B) and a β-1,4-galactosidase-treated NISTmAb (sample A). …”
-
100